The Impact of Liquid Biopsy in Advanced Ovarian Cancer Care
Diagnostics · 26.08.2024 · 14 (17) · 1868
DOI: 10.3390/diagnostics14171868 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 26.08.2024. Verfasst von Antoni Llueca und 15 weiteren Autor:innen. Beteiligte Einrichtung: Reference Unit of Abdominal Pelvic Oncology Surgery (RUAPOS), General University Hospital of Castellón, 12004 Castellón, Spain. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundacion Hospital Provincial de Castellon.spain, Fundacion Hospital Provincial de Castellon, Sociedad de Obstetricia y Ginecología de la Comunidad Valenciana.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Ovarian cancer is the third most common gynaecological cancer and has a very high mortality rate. The cornerstone of treatment is complete debulking surgery plus chemotherapy. Even with treatment, 80% of patients have a recurrence. Circulating tumour DNA (ctDNA) has been shown to be useful in the control and follow-up of some tumours. It could be an option to define complete cytoreduction and for the early diagnosis of recurrence.
Objective
We aimed to demonstrate the usefulness of ctDNA and cell-free DNA (cfDNA) as a marker of complete cytoreduction and during follow-up in patients with advanced ovarian cancer. Material and Methods: We selected 22 women diagnosed with advanced high-grade serous ovarian cancer, of which only 4 had complete records. We detected cfDNA by polymerase chain reaction (PCR), presented as ng/mL, and detected ctDNA with droplet digital PCR (ddPCR). We calculated Pearson correlation coefficients to evaluate correlations among cfDNA, ctDNA, and cancer antigen 125 (CA125), a biomarker.
Results
The results obtained in the evaluation of cfDNA and ctDNA and their correlation with tumour markers and the radiology of patients with complete follow-up show disease progression during the disease, stable disease, or signs of recurrence. cfDNA and ctDNA correlated significantly with CA125. Following cfDNA and ctDNA over time indicated a recurrence several months earlier than computed tomography and CA125 changes.
Conclusion
An analysis of cfDNA and ctDNA offers a non-invasive clinical tool for monitoring the primary tumour to establish a complete cytoreduction and to diagnose recurrence early.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Reference Unit of Abdominal Pelvic Oncology Surgery (RUAPOS), General University Hospital of Castellón, 12004 Castellón, Spain.
- Oncological Surgery Research Group (OSRG), Department of Medicine, University Jaume I (UJI), 12071 Castellon, Spain.
- Department of Mathematics, IMAC (Institut Universitari de Matematiques i Aplicacions de Castelló), University Jaume I (UJI), 12071 Castellon, Spain.
- Department of Molecular Biology, Hospital Provincial de Castellon, 12002 Castellón, Spain.
- Research Laboratory in Biomarkers in Reproduction, Gynaecology and Obstetrics, Research Foundation of the General University Hospital of Valencia, 46014 Valencia, Spain.
- Pathology Department, General University Hospital of Valencia Consortium, 46014 Valencia, Spain.
ORCID-Profile: Antoni Llueca, Sarai Canete-Mota, Anna Jaureguí, Manuela Barneo, Maria Victoria Ibañez, Alexander Neef, Enrique Ochoa, Sarai Tomas-Perez, Josep Mari-Alexandre, Anna Serra
Förderung
- Fundacion Hospital Provincial de Castellon.spain
- Fundacion Hospital Provincial de Castellon
- Sociedad de Obstetricia y Ginecología de la Comunidad Valenciana
- Fundación para la Investigación del Hospital General Universitario de Valencia
- Junta Asociada Provincial de Valencia de la Asociación Española Contra el Cáncer
Zitieren
APA
Llueca, A., Canete-Mota, S., Jaureguí, A., Barneo, M., Ibañez, M. V., Neef, A., Ochoa, E., Tomas-Perez, S., Mari-Alexandre, J., Gilabert-Estelles, J., Serra, A., Climent, M. T., Bellido, C., Ruiz, N., Segarra-Vidal, B., & Llueca, M. (2024). The Impact of Liquid Biopsy in Advanced Ovarian Cancer Care. Diagnostics, 14(17), 1868. https://doi.org/10.3390/diagnostics14171868
Vancouver
Llueca A, Canete-Mota S, Jaureguí A, Barneo M, Ibañez MV, Neef A, et al. The Impact of Liquid Biopsy in Advanced Ovarian Cancer Care. Diagnostics. 2024;14(17):1868. doi:10.3390/diagnostics14171868
BibTeX
@article{Llueca2024,
author = {Llueca, Antoni and Canete-Mota, Sarai and Jaureguí, Anna and Barneo, Manuela and Ibañez, Maria Victoria and Neef, Alexander and Ochoa, Enrique and Tomas-Perez, Sarai and Mari-Alexandre, Josep and Gilabert-Estelles, Juan and Serra, Anna and Climent, Maria Teresa and Bellido, Carla and Ruiz, Nuria and Segarra-Vidal, Blanca and Llueca, Maria},
title = {The Impact of Liquid Biopsy in Advanced Ovarian Cancer Care},
journal = {Diagnostics},
year = {2024},
volume = {14},
number = {17},
pages = {1868},
doi = {10.3390/diagnostics14171868}
}
EUVIMED